Eligibility criteria and selection of studies
The SR included RCTs comparing dupilumab versus placebo added to usual
care/standard of care in patient with moderate-to-severe AD, and
reporting one of the outcomes of interest as formulated by the GDG
(figure 1 A and B). The SR excluded studies with dose or route not
approved by the EMA or FDA, papers published as abstract or conference
communications or not published in English. After initial calibration
two reviewers independently screened the search results based on the
title and abstract followed by independent assessment of the eligibility
based on the full text. In case of disagreement a third reviewer was
consulted. References were managed with Endnote version X9 software
(Thomson Reuters, New York, USA).